Physician profile
Carlos Rivera
NPI 1992741326
$1,662.01
in general payments reported to CMS, 2019-2025
22 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $160 · 2021: $373 · 2022: $281 · 2023: $326 · 2024: $201 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.39 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243.92 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $231.59 | 2019-2024 | Creon |
| Astrazeneca Pharmaceuticals LP | $177.25 | 2019-2025 | Breztri |
| Opko Pharmaceuticals, LLC | $164.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $123.90 | 2019-2023 | Steglatro |
| Amgen INC. | $110.72 | 2023-2025 | Repatha, Otezla, Repatha |
| Paratek Pharmaceuticals, INC. | $95.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.07 | 2023 | |
| Corcept Therapeutics | $61.51 | 2024-2025 | Korlym |
| Lilly USA, LLC | $45.30 | 2023-2025 | Jardiance, Mounjaro |
| Abiomed | $44.17 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.33 | 2022-2025 | Jardiance |
| Shield Therapeutics INC | $42.07 | 2022 | |
| Exact Sciences Corporation | $41.36 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $36.85 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.53 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $30.06 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $24.78 | 2019 | |
| Horizon Therapeutics Plc | $14.67 | 2021 | |
| Pfizer INC. | $13.93 | 2019 | |
| Allergan, INC. | $13.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.